Published in J Antimicrob Chemother on June 01, 2001
The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med (2005) 1.63
Drug delivery systems: An updated review. Int J Pharm Investig (2012) 1.31
Tuberculosis chemotherapy: current drug delivery approaches. Respir Res (2006) 1.11
Dendrimeric micelles for controlled drug release and targeted delivery. Mol Pharm (2005) 0.91
Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice. Sci Rep (2013) 0.82
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother (2003) 0.78
Formulation and in vitro evaluation of rifampicin loaded porous microspheres. Sci Pharm (2010) 0.76
Antitubercular effect of 8-[(4-Chloro phenyl) sulfonyl]-7-Hydroxy-4-Methyl-2H-chromen-2-One in guinea pigs. J Pharmacol Pharmacother (2011) 0.75
Novel drug delivery systems: desired feat for tuberculosis. J Adv Pharm Technol Res (2010) 0.75
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) (2005) 1.25
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) (2003) 1.18
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J (2000) 1.15
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents (2005) 1.14
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother (2005) 1.11
Phospholipids of Clostridium butyricum. V. Effects of growth temperature on fatty acid, alk-1-enyl ether group, and phospholipid composition. J Lipid Res (1974) 1.09
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm (2005) 1.04
Signaling through protein kinases and transcriptional regulators in Candida albicans. Crit Rev Microbiol (2003) 1.02
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother (2001) 1.01
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother (2004) 0.99
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm (2002) 0.99
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents (2001) 0.97
Further studies on the lipids of corynebacteria. The mannolipids of Corynebacterium aquaticum. Biochem J (1972) 0.96
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol (2007) 0.95
Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents (2004) 0.94
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (1997) 0.94
Effects of growth temperature and supplementation with exogenous fatty acids on some physical properties of Clostridium butyricum phospholipids. Biochim Biophys Acta (1977) 0.94
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis (2004) 0.93
Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) (2005) 0.92
On the mannophosphoinositides of Mycobacterium 607. Experientia (1968) 0.92
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother (2006) 0.92
Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra. Arch Microbiol (1999) 0.92
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 0.92
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents (2007) 0.91
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother (2003) 0.91
Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother (2004) 0.91
Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif (2006) 0.90
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci (2008) 0.90
Comparative evaluation of the diagnostic significance of circulating immune complexes and antibodies to phosphatidylinositomannosides in pulmonary tuberculosis by enzyme-linked immunosorbent assay. Med Microbiol Immunol (1989) 0.90
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother (2004) 0.90
Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Eur Respir J (2006) 0.89
DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol (2001) 0.88
Effect of acute administration of dichlorodiphenyl trichloroethane on certain enzymes of Rhesus monkey. Indian J Med Res (1978) 0.88
Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine (2005) 0.88
Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H37Ra. Med Microbiol Immunol (1997) 0.88
Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1990) 0.88
Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes. J Med Microbiol (1989) 0.87
Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine (2005) 0.87
Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv (2004) 0.87
Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol (2007) 0.86
Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study. Int J Antimicrob Agents (2001) 0.86
Replacement of acyl and alk-1-enyl groups in Clostridium butyricum phospholipids by exogenous fatty acids. Biochemistry (1975) 0.86
Lipid metabolism in fungi. Crit Rev Microbiol (1984) 0.86
Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J Biochem Biophys (1993) 0.86
Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta (1997) 0.85
Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006) 0.85
Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv (2008) 0.84
Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J (2005) 0.83
Effect of growth temperature on the lipid composition of Mycobacterium smegmatis ATCC 607. J Gen Microbiol (1979) 0.83
Antigenicity of phosphatidyl inositomannosides of Mycobacterium tuberculosis. Immunochemistry (1971) 0.83
Alterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatis. Lett Appl Microbiol (1999) 0.83
Lipid composition and virulence of Mycobacterium tuberculosis H37Rv. Aust J Exp Biol Med Sci (1982) 0.83
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (2001) 0.82
Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents (2004) 0.82
Role of cyclic adenosine monophosphate in phospholipid synthesis in Mycobacterium smegmatis ATCC 607. Lipids (1995) 0.81
Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol (1998) 0.81
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol (1994) 0.81
Ca2+/calmodulin dependent protein kinase from Mycobacterium smegmatis ATCC 607. Mol Cell Biochem (1998) 0.81
Acid phosphatase activity of promastigotes of Leishmania donovani: a marker of virulence. FEMS Microbiol Lett (1992) 0.80
Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. Indian J Biochem Biophys (1989) 0.80
On the ornithinyl ester of phosphatidylglycerol of Mycobacterium 607. J Bacteriol (1970) 0.80
Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Med Microbiol Immunol (1988) 0.80
Phospholipid metabolism in Mycobacterium smegmatis ATCC 607 grown at 37 degrees and 27 C degrees C. Arch Microbiol (1981) 0.80
Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra. Vaccine (1997) 0.79
The mannophosphoinositides of the unclassified Mycobacterium P 6 . Am Rev Respir Dis (1972) 0.79
Detection of mannophosphoinositide antigens in sputum of tuberculosis patients by dot enzyme immunoassay. Med Microbiol Immunol (1991) 0.79
Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications. Indian J Exp Biol (2006) 0.78
Effect of fatty acid supplementation on the lipid composition of Mycobacterium smegmatis ATCC 607, grown at 27 degrees and 37 degrees C. J Appl Bacteriol (1983) 0.78
Subcellular localization of enzymes of phospholipid metabolism in Candida albicans. J Med Vet Mycol (1990) 0.78
The polar lipids of some species of Nocardia. J Gen Microbiol (1972) 0.78
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother (2003) 0.78
Poly (DL-lactide-co-glycolide) based delivery systems for vaccines and drugs. Indian J Exp Biol (2000) 0.78
Changes in phospholipid composition of Nocardia polychromogenes during temperature adaptation. Experientia (1977) 0.78
Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv (2006) 0.78
Cell cycle effects of the phenothiazines: trifluoperazine and chlorpromazine in Candida albicans. FEMS Microbiol Lett (2001) 0.78
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents (2009) 0.77
Influence of aminophylline on the lipids in Microsporum gypseum. Biochim Biophys Acta (1991) 0.77
Lipids of dermatophytes. Lipids (1981) 0.77
Possible involvement of Ca2+/calmodulin-dependent protein kinase in the regulation of phospholipid biosynthesis in Microsporum gypseum. Mol Cell Biochem (1999) 0.77
Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. Indian J Exp Biol (2004) 0.77
Effect of age on the composition of major phospholipids of mycobacteria. Indian J Biochem Biophys (1972) 0.77
Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J Exp Biol (2006) 0.77
Calcium induced alterations in structural and functional role of phospholipids in Microsporum gypseum. Indian J Biochem Biophys (1995) 0.77
Identification, localization and possible role of calmodulin like protein in phospholipid synthesis of Microsporum gypseum. Biochim Biophys Acta (1995) 0.77
Effect of choline, ethanolamine and serine supplementation on the membrane properties of Microsporum gypseum. Lipids (1987) 0.77
Correlation between intracellular cAMP levels and phospholipids of Microsporum gypseum. Biochim Biophys Acta (1992) 0.77
Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents (2002) 0.77
Effect of ethambutol on the phospholipids of ethambutol susceptible and resistant strains of Mycobacterium smegmatis ATCC 607. Indian J Biochem Biophys (1990) 0.77
Subcellular distribution of mannophosphoinositides in Mycobacterium smegmatis during growth. Experientia (1983) 0.77
Metabolism of lipids in Epidermophyton floccosum. Indian J Med Res (1981) 0.77
Lipids of pathogenic fungi. Prog Lipid Res (1983) 0.77
In vivo studies on phospholipid biosynthesis in Microsporum gypseum. Indian J Med Res (1982) 0.76